IN8Bio

IN8bio was founded with the mission of developing next-generation cellular therapies for treating cancer. IN8bio is located in New York City with its primary scientific operations in Birmingham, Alabama. We are a leading clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for solid and hematological tumors. We are one of the most advanced gamma-delta T cell companies and were the first to bring genetically modified gamma-delta T cells into the clinic. We are utilizing our suite of DeltEx platform technologies to achieve our mission of what we refer to as CANCER ZERO ─ the elimination of all cancer cells in every patient battling the disease. We develop ex vivo expanded and activated gamma-delta T cell therapeutic candidates based upon our deep expertise in gamma-delta T cell biology, proprietary genetic engineering and cell-type specific manufacturing capabilities, collectively known as our DeltEx platform. We are dedicated to leveraging our DeltEx platform to develop next-generation cellular therapies that we believe can dramatically improve outcomes for cancer patients. We are led by William Ho, our founder and Chief Executive Officer, who has over 22 years of experience in healthcare finance, investing and managing biotech companies.